Mallinckrodt Puts Down $1.3B To Acquire Cadence
Irish specialty pharmaceutical company Mallinckrodt PLC will buy Cadence Pharmaceuticals Inc. for $1.3 billion, the companies said Tuesday, in a deal that nets Mallinckrodt a Cadence portfolio that includes the pain...To view the full article, register now.
Already a subscriber? Click here to view full article